Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients-Reference-Cited by-同舟云学术

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Published:2018-08-28 Issue:24 Volume:24 Page:6345-6354
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Tallón de Lara Paulino,Cecconi Virginia,Hiltbrunner Stefanie,Yagita Hideo,Friess Martina,Bode Beata,Opitz Isabelle,Vrugt Bart,Weder Walter,Stolzmann Paul,Felley-Bosco Emanuela,Stahel Rolf A.,Tischler Verena,Britschgi Christian,Soldini Davide,van den Broek Maries,Curioni-Fontecedro Alessandra

Funder

Swiss National Science Foundation

Science Foundation for Oncology

Forschungskredit University of Zurich

Sophien Stiftung Zurich

University Research Priority Program Zurich

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials;International Immunopharmacology;2024-09

2. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors;Targeted Oncology;2023-12-08

3. Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL;Cancers;2023-08-20

4. The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer;Cancers;2023-08-15

5. Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity;Clinical and Translational Oncology;2023-04-19